Jun 15, 2026 09:15AM
Jun 15, 2026 09:15AM
May 14, 2026 04:02PM
Apr 21, 2026 04:06PM
Apr 21, 2026 04:05PM
Apr 20, 2026 05:03PM
Mar 19, 2026 04:00PM Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Dec 16, 2025 05:00PM
Dec 16, 2025 05:00PM
Nov 14, 2025 06:00AM
Oct 23, 2025 04:08PM
Oct 23, 2025 04:05PM
Oct 22, 2025 04:01PM
Jan 21, 2025 05:01PM Inhibrx Inc. (INBX) Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Jan 21, 2025 05:01PM
May 24, 2024 04:01PM
May 24, 2024 04:00PM
May 10, 2024 06:36PM
May 8, 2024 04:37PM
Feb 28, 2024 09:15AM
Jan 23, 2024 04:05AM Inhibrx (INBX) Sells INBRX-101 to Sanofi (SNY) for Up to $2.2B
Jan 23, 2024 01:00AM
Nov 2, 2023 09:22AM
Nov 2, 2023 09:15AM
Sep 19, 2023 04:00PM
Sep 19, 2023 04:00PM
Aug 7, 2023 04:00PM
May 30, 2023 09:02AM Inhibrx (INBX) Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
May 30, 2023 09:00AM
May 15, 2023 06:27AM
May 8, 2023 04:05PM
Apr 26, 2023 09:05AM
Apr 26, 2023 09:00AM
Nov 16, 2022 09:01AM
Nov 16, 2022 09:00AM Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma
Nov 7, 2022 04:05PM
Oct 4, 2022 08:01AM
Oct 4, 2022 08:00AM
Oct 3, 2022 04:31PM
Oct 3, 2022 04:30PM
Aug 23, 2022 07:45AM
Aug 15, 2022 04:06PM Inhibrx Inc. (INBX) Granted Orphan Drug Designation to INBRX-109 by EMA
Aug 15, 2022 04:05PM
May 19, 2022 04:05PM
May 16, 2022 09:01AM
May 16, 2022 09:00AM
May 9, 2022 04:05PM
Mar 3, 2022 09:16AM
Mar 3, 2022 09:15AM Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
Feb 28, 2022 04:05PM

323,146 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All